Resumen:
Purpose. To assess the emetogenic potential of different chemotherapy (CT) regimens in daily clinical practice in an outpatient
setting. To optimize antiemetic prophylaxis if necessary
Methods. Prospective and retrospective review of the emetogenic potential of CT regimens used in adult patients in an outpatient
setting
Results. We assess the chemotherapy-induced nausea and vomiting (CINV) of 50 different CT regimens used on 157 different
patients in an outpatient setting. We found that the CT usually classified as highly emetogenic, including cisplatin and
anthracycline-cyclophosphamide combination, had the higher incidence of CINV (37.5 and 54.4% respectively). The antineoplastic
drugs usually considered to be moderately emetogenic had, as expected, lower rates of emesis with the exception of
irinotecan, which presented a pattern of nausea and/or vomiting (NV) similar to the highly emetogenic CTwith a global incidence
of 48.5%. The appearance of emetic symptoms had impact on quality of life in 70% of the patients, with nausea being the main
emetic symptom.
Conclusion. Antiemetic prophylaxis for highly emetogenic CTcould be improve. Irinotecan CTregimens have a high emetogenic
potential more than moderate and require more intensive antiemetic prophylaxis too.
